Breast cancer is a serious and most common problem in developed as well as developing countries.
About 1 in 8 U.S. women summing up to 12% are at the risk of developing invasive breast cancer over the course of her lifetime. And if we talk about the present scenario, there are over 3 million women in the United States, who have been diagnosed with breast cancer, a study by revealed. Moreover, around 2,670 men will be diagnosed with breast cancer at some point in life.

What are the survival rates?

Breast cancer is the second-most common cause of death in women after lung cancer. However, the number of women dying due to it has lowered down gradually owing to improved diagnosis and treatment methods.

Different sub-types of Breast cancer affect people differently. Some behave aggressively on some compared to others, some tend to prevail due to fewer feasible treatment options. There exist other factors like if cancer has spread to other parts of the body like bones i.e., extent and location of the metastasis that affect the long-term survival of the patients.

Immediate treatment and the effectiveness of the therapy can also improve the survival rates.

According to a survey by, the average 5-year survival rate for women with invasive breast cancer is 90% I.e., 90% of women living with invasive breast cancer will survive for at least 5 years. Whereas the per cent for 10-year survival rate falls to 83%.

Furthermore, the 5-year survival rate in case of metastatic cancer falls depending upon the part cancer has invaded.

Know your Type

Knowing the type of breast cancer is as important as knowing the disorder a woman is suffering from. The genetic makeup of the tumour helps physicians detect and choose the right approach to treat cancer.

Status of hormone receptor (HR) and human epidermal growth factor receptor- 2 (HER-2) defines the type of breast cancer. These two receptors can either be present or absent.

HR-positive/HER2-negative breast cancer is the most common form of breast cancer, accounting for more than 70% of all the breast cancers.

HR-positive/ Her-negative Breast cancer is usually treated with hormone therapies or a combination of hormone therapy with targeted therapy to help stop tumour growth first. However, sometimes cancer outsmarts the treatment and becomes resistant to hormonal therapy and stops working.

HR-positive/HER2-negative breast cancer Epidemiology

According to DelveInsight’s epidemiology model, HR-positive/ HER2-negative Breast Cancer total incident population in the 7MM is expected to grow at CAGR of 0.83%, during the study period 2017–2028.

Moreover, the United States accounted for higher HR-positive Breast cancer incidence, with 266,120 cases in 2017. Taking into account EU5 countries, Germany led the charts with 71,585 cases in 2017, followed by Italy, with Spain accounting for the least number of Breast cancer incident cases equivalent to 11.99% of the total EU-5 breast cancer cases.

Furthermore, Japan accounted for the second-highest breast cancer incident cases with 89,100 making up 14.21% of the total breast cancer incident population.

In 7MM, HR-positive/HER2-negative breast cancer occupies the maximum patient pool, followed by the number of those with Triple-negative and HR-positive/HER2-positive, the exception being Japan. On the other hand, HR-negative/HER2-positive accommodated the least number of cases.

HR-positive/ HER2-negative Breast Cancer Market Outlook

The HR-positive/ HER2-negative Breast cancer market size in the 7MM countries was observed to be USD 5,237.2 million in 2017.

In 7MM, the US dominates the highest HR-positive/HER2-negative breast cancer market share in 2017 accounting for approximately 83.96% of the total market.

Owing to the approval of new treatment and therapies, the HR-positive Breast cancer market is booming forward. The HR-positive/HER2-negative breast cancer market size was found to be USD 4216.4 million in 2017, as per DelveInsight’s analysis.

Germany had the highest market size of HR-positive/HER2-negative breast cancer in 2017, which accounts for approximately 25.51% of the total HR-positive Breast cancer market. Of all the prescribed first-line therapies, CDK4/6 inhibitors occupy the maximum market share, Ibrance leading the charts, followed by Kisqali and Verzenio. Moreover, the expiry of the patent of Ibrance in the year 2023 will further add to the revenues generated by Kisqali and Verzenio in coming years.

The second position in the first-line treatment options is occupied by SERD class (Faslodex).

Endocrine therapy is recognized as the preferred option for hormone-receptor-positive breast cancer only when it is assured that there are no chances of visceral crisis or concern/proof of endocrine resistance.

The therapy inhibits the growth of a tumour. Numerous endocrine agents such as aromatase inhibitors (anastrozole, letrozole, exemestane), estrogen receptor modulators (tamoxifen) and selective estrogen receptor degraders or down-regulators(fulvestrant) have been manufactured to slow down the cancer progression.

Companies working to fuel the HR-positive/ HER2-negative Breast Cancer market

More than a dozen companies including Jiangsu HengRui Medicine Co., Odonate Therapeutics, Radius Pharmaceuticals, Immunomedics, Roche Group Syndax Pharmaceuticals, Merck Sharp & Dohme Corp, Eagle Pharmaceuticals and others are involved to advance the HR-positive/ HER2-negative Breast Cancer Market.